Denali Therapeutics (DNLI) Current Leases (2019 - 2025)
Denali Therapeutics (DNLI) reported Current Leases of $9.2 million for Q3 2025, up 14.04% year-over-year from $8.0 million in Q3 2024, and up 3.3% on a QoQ basis from $8.9 million in Q2 2025.
Denali Therapeutics (DNLI) has 7 years of Current Leases data on file, last reported at $9.2 million in Q3 2025.
- Quarterly Current Leases rose 14.04% year-over-year to $9.2 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $9.2 million (up 14.04% YoY) and the FY2024 annual result came in at $8.3 million, up 14.44% from the prior year.
- Current Leases rose to $9.2 million in Q3 2025 per DNLI's latest filing, from $8.9 million in the prior quarter.
- Across five years, Current Leases topped out at $9.2 million in Q3 2025 and bottomed at $4.9 million in Q1 2021.
- The 5-year median for Current Leases is $7.1 million (2022), against an average of $7.0 million.
- The widest annual swing landed in 2022, when Current Leases jumped 34.58%; it then declined 0.79% in 2023.
- Tracing DNLI's Current Leases over 5 years: stood at $5.5 million in 2021, then jumped by 34.2% to $7.3 million in 2022, then retreated by 0.79% to $7.3 million in 2023, then gained by 14.44% to $8.3 million in 2024, then rose by 10.3% to $9.2 million in 2025.
- Per Business Quant, the three latest DNLI Current Leases figures stand at $9.2 million (Q3 2025), $8.9 million (Q2 2025), and $8.6 million (Q1 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 83,991.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 7.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 720.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 45.66 Mn |
| 10 | Denali Therapeutics | 3.82 Bn | 3.82 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 9.16 Mn |
| Jun 30, 2025 | 8.87 Mn |
| Mar 31, 2025 | 8.59 Mn |
| Dec 31, 2024 | 8.31 Mn |
| Sep 30, 2024 | 8.04 Mn |
| Jun 30, 2024 | 7.77 Mn |
| Mar 31, 2024 | 7.51 Mn |
| Dec 31, 2023 | 7.26 Mn |
| Sep 30, 2023 | 7.01 Mn |
| Jun 30, 2023 | 6.77 Mn |
| Mar 31, 2023 | 6.54 Mn |
| Dec 31, 2022 | 7.32 Mn |
| Sep 30, 2022 | 7.07 Mn |
| Jun 30, 2022 | 5.87 Mn |
| Mar 31, 2022 | 5.66 Mn |
| Dec 31, 2021 | 5.45 Mn |
| Sep 30, 2021 | 5.25 Mn |
| Jun 30, 2021 | 5.06 Mn |
| Mar 31, 2021 | 4.88 Mn |
| Dec 31, 2020 | 4.69 Mn |
| Sep 30, 2020 | 4.51 Mn |
| Jun 30, 2020 | 4.33 Mn |
| Mar 31, 2020 | 4.12 Mn |
| Dec 31, 2019 | 3.67 Mn |